Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
About
About
EQOH
Careers
Contact Us
EMJ Gold
search
Subscribe
FREE
Subscribe to EMJ GOLD
Subscribe to EMJ
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
About
About
EQOH
Careers
Contact Us
EMJ Gold
Subscribe
FREE
Subscribe to EMJ GOLD
Subscribe to EMJ
Edition
European
US
Oncology
Filter
Journals
About
Congress reviews
Abstracts
Articles
Podcasts
Videos & Webinars
News
Infographics
Submit A Paper
Shared Insights on Treating BRAF
V600
-mutant Metastatic Cancers
September 2024
Shared Perspectives on Targeted Therapies for Metastatic BRAFV600 Mutations. Recorded live from Barcelona, Spain, during the 2024…
Read more
4th February 2016
Cardio-oncology in multiple myeloma
Ola Landgren, MD, PhD from National Cancer Institute, Bethesda, MD talks about cardio-oncology in multiple myeloma (MM). In this new era of more…
4th February 2016
Phase 3 trials of atezolizumab versus standard chemotherapy in PD-L1-selected NSCLC
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Roy S. Herbst, MD, PhD…
4th February 2016
LUX-Lung 7: Phase 2b trial of afatinib versus gefitinib for EGFR-mutated adenocarcinoma of the lung
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Roy S. Herbst, MD, PhD…
4th February 2016
AZD9291, an EGFR-TKI, for T790M-mediated resistance in non-small cell lung cancer
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Pasi A. Jänne, MD, PhD…
4th February 2016
LUX-Lung 7: Phase 2b trial of afatinib versus gefitinib for EGFR-mutated lung cancer in first-line
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Pasi A. Jänne, MD, PhD…
4th February 2016
Oncogene-addicted non-small cell lung cancer
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Pasi A. Jänne, MD, PhD…
4th February 2016
Quality of life and new therapeutic options for metastatic castration-resistant prostate cancer
At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Hilary Glen, MbChB, MSc, PhD, FRCP, of the Beatson West of Scotland Cancer…
2nd February 2016
Learn more about the ESMO Asia 2015 Congress
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, ESMO and Congress…
Loading posts...
« Previous
1
…
10
11
12
13
14
…
42
Next »